SCHEMBL5534779

SCHEMBL5534779

O=[C]OCc1scnc1-c1ccccc1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.36
NR1H4 Q96RI1 3/20 0.35
DPP4 P27487 1/20 0.35
PSMB8 P28062 1/20 0.35
NOTUM Q6P988 1/20 0.35
MAOB P27338 2/20 0.34
ALDH1A1 P00352 4/20 0.33
CYP2D6 P10635 4/20 0.33
CYP2C19 P33261 4/20 0.33
CYP3A4 P08684 3/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CDC7 O00311 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
DBF4 Q9UBU7 1/20 0.33
KMO O15229 2/20 0.33
HPGD P15428 1/20 0.33
HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544619 0.83 MAPK14 (0.38) DPP4NOTUMMAOBALDH1A1
SCHEMBL5537449 0.80 ADORA2A (0.33) FFAR4DPP4NOTUMMAPK1
SCHEMBL5536451 0.80 PSMB8 (0.35) FFAR4DPP4PSMB8NOTUMALDH1A1
SCHEMBL28015141 0.78 DPP4 (0.35) DPP4
SCHEMBL5538359 0.76 FFAR4 (0.37) FFAR4CYP1A2
SCHEMBL5539845 0.73 PIM1 (0.43) PSMB8NOTUMALDH1A1MAPK1HSD17B10
SCHEMBL5537646 0.72 NR1H2 (0.38)
SCHEMBL5536697 0.72 ALDH1A1 (0.41) FFAR4PSMB8NOTUMALDH1A1CYP2D6
SCHEMBL5544714 0.72 AVPR2 (0.41) FFAR4PSMB8NOTUMALDH1A1CYP2D6
SCHEMBL5548160 0.70 MAPT (0.34) FFAR4ALDH1A1CYP2C19ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 FFAR4 338/4885NR1H4 171/4885DPP4 3965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.